FDA issues Safety Alert for clarithromycin
Editor's Note
The Food and Drug Administration (FDA) on February 22 issued a Safety Alert for clarithromycin (Biaxin) because of the potential increased risk of heart problems or death associated with this antibiotic in patients with heart disease.
A large clinical trial with 10-year follow-up found an unexpected increase in deaths among coronary heart disease patients 1 year or longer after receiving a 2-week course of clarithromycin.
As a result, the FDA is advising prescribers to consider using other antibiotics in such patients and has added the study results to the drug label.
Posted 02/22/2018] AUDIENCE: Health Professional, Internal Medicine, Cardiology, Patient ISSUE: FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later.
Free Daily News
- Study: Knee arthritis surgery neither delays nor hastens total replacement
- Study: Reverse total shoulder replacement long-term outcomes similar to traditional surgery
- Wearables could help surgeons maintain healthy posture during lengthy procedures
- Robotic-assisted total knee replacements: Improved outcomes, higher costs
- Analyzing impact of long COVID on cognitive health, surgical outcomes
- Study: Bariatric surgery improves kidney transplant eligibility for patients with obesity
- Premature mortality rates higher for lesbian, bisexual female nurses
- Lit-up landmarks spotlight caretaker contributions for National Nurses Week
- Study: Nurses ideally positioned but not sufficiently educated to combat human trafficking
- State grant helps build healthcare talent pipeline